Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Free Report)’s stock price rose 3.7% on Friday . The company traded as high as $25.02 and last traded at $25.02. Approximately 3,835 shares were traded during mid-day trading, an increase of 1,146% from the average daily volume of 308 shares. The stock had previously closed at $24.12.
Wall Street Analyst Weigh In
Separately, Royal Bank of Canada upgraded Hikma Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Tuesday, December 10th.
View Our Latest Stock Analysis on HKMPF
Hikma Pharmaceuticals Stock Performance
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Articles
- Five stocks we like better than Hikma Pharmaceuticals
- P/E Ratio Calculation: How to Assess Stocks
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- 3 Best Fintech Stocks for a Portfolio Boost
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- How to Calculate Return on Investment (ROI)
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
